Attached files
| file | filename |
|---|---|
| 8-K/A - AMENDMENT NO. 2 TO FORM 8-K - Element Solutions Inc | d834966d8ka.htm |
| EX-99.1 - EX-99.1 - Element Solutions Inc | d834966dex991.htm |
Exhibit 99.2
Arysta LifeScience Limited
Interim Condensed Consolidated Financial Statements
Interim Condensed Consolidated Income Statement
| Six months ended June 30, | ||||||||
| (U.S. dollars in thousands) | 2013 | 2014 | ||||||
| (unaudited) | (unaudited) | |||||||
| Continuing operations |
||||||||
| Sales |
$ | 678,903 | $ | 699,646 | ||||
| Cost of goods sold |
(437,040 | ) | (438,958 | ) | ||||
|
|
|
|
|
|||||
| Gross profit |
241,863 | 260,688 | ||||||
|
|
|
|
|
|||||
| Selling, general and administrative expense |
(166,221 | ) | (176,471 | ) | ||||
| Other operating income |
220 | 479 | ||||||
| Other operating expense |
(1,498 | ) | (949 | ) | ||||
|
|
|
|
|
|||||
| Operating income |
74,364 | 83,747 | ||||||
|
|
|
|
|
|||||
| Interest income |
10,658 | 9,517 | ||||||
| Other financial income |
29,223 | 5,137 | ||||||
|
|
|
|
|
|||||
| Financial income |
39,881 | 14,654 | ||||||
|
|
|
|
|
|||||
| Interest expense |
(79,782 | ) | (54,602 | ) | ||||
| Other financial expense |
(18,155 | ) | (27,322 | ) | ||||
|
|
|
|
|
|||||
| Financial expense |
(97,937 | ) | (81,924 | ) | ||||
|
|
|
|
|
|||||
| Income (loss) before tax from continuing operations |
16,308 | 16,477 | ||||||
|
|
|
|
|
|||||
| Income tax benefit (expense) |
(47,751 | ) | (35,745 | ) | ||||
|
|
|
|
|
|||||
| Income (loss) after tax from continuing operations |
$ | (31,443 | ) | $ | (19,268 | ) | ||
|
|
|
|
|
|||||
| Discontinued operations |
||||||||
| Income (loss) after tax from discontinued operations |
(2,912 | ) | (688 | ) | ||||
|
|
|
|
|
|||||
| Net income (loss) |
$ | (34,355 | ) | $ | (19,956 | ) | ||
|
|
|
|
|
|||||
| Attributable to: |
||||||||
| Arysta LifeScience Limited (“ALS”) shareholder |
$ | (39,109 | ) | $ | (23,581 | ) | ||
| Non-controlling interests |
4,754 | 3,625 | ||||||
|
|
|
|
|
|||||
| Net income (loss) |
$ | (34,355 | ) | $ | (19,956 | ) | ||
|
|
|
|
|
|||||
| Earnings (loss) per share |
||||||||
| Continuing operations |
$ | (36,197 | ) | $ | (22,893 | ) | ||
| Discontinued operations |
(2,912 | ) | (688 | ) | ||||
|
|
|
|
|
|||||
| Basic and diluted earnings (loss) per share |
$ | (39,109 | ) | $ | (23,581 | ) | ||
|
|
|
|
|
|||||
| Weighted average shares used to compute earnings (loss) per share |
||||||||
|
|
|
|
|
|||||
| Basic and diluted |
1 | 1 | ||||||
|
|
|
|
|
|||||
The accompanying notes form an integral part of the interim condensed consolidated financial statements.
Arysta LifeScience Limited
Interim Condensed Consolidated Financial Statements
| 5. | Earnings (loss) per Share |
Basic and diluted earnings per share (“EPS”) amounts are calculated by dividing the net income (loss) for the six months attributable to ordinary equity holders of the company by the weighted average number of ordinary shares outstanding during the six months as the Group has not issued any potentially dilutive securities, such as stock options or stock appreciation lights.
There have been no other transactions involving ordinary shares or ordinary shares between the reporting date and the date of authorization of these financial statements.
The following reflects the income and share data used in the basic and diluted earnings per share computations:
| Six months ended June 30, |
||||||||
| (U.S. dollars in thousands) |
2013 | 2014 | ||||||
| Net income (loss) attributable to shareholder of ALS from continuing operations |
$ | (36,197 | ) | $ | (22,893 | ) | ||
| Net income (loss) attributable to shareholder of ALS from discontinued operations |
(2,912 | ) | (688 | ) | ||||
|
|
|
|
|
|||||
| Net income (loss) attributable to shareholder of ALS |
$ | (39,109 | ) | $ | (23,581 | ) | ||
|
|
|
|
|
|||||
| Six months ended June 30, |
||||||||
| 2013 | 2014 | |||||||
| Weighted average number of shares - basic and diluted |
1 | 1 | ||||||
|
|
|
|
|
|||||
| Six months ended June 30, |
||||||||
| (U.S. dollars in thousands) |
2013 | 2014 | ||||||
| Basic and diluted EPS attributable to ordinary shareholder of ALS |
$ | (39,109 | ) | $ | (23,581 | ) | ||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
| Basic and diluted EPS from continuing operations |
$ | (36,197 | ) | $ | (22,893 | ) | ||
|
|
|
|
|
|||||